Filter By Category
Archives
Share on -
AZINTUXIZUMAB VEDOTIN
Generic Name: AZINTUXIZUMAB VEDOTIN
ABSTRACT -
Azintuxizumab vedotin, also known as ABBV-838, is an antibody-drug conjugate composed of an anti-CS1/SLAMF7/CD319 antibody linked through a cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxic payload. It was investigated in relapsed or refractory multiple myeloma. ADCs are biologic conjugates and do not have a single conventional small-molecule skeletal structure. Development/regulatory status: Investigational/discontinued phase 1 development for multiple myeloma.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Dosing in clinical studies was protocol-directed intravenous infusion with dose escalation and safety monitoring.
- Dose depends on body weight, trial cohort, prior therapies, cytopenias, organ function, and toxicity.
- Do not administer outside oncology clinical research or approved specialist use.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Peripheral neuropathy, fatigue, nausea, or diarrhoea
- Neutropenia, thrombocytopenia, anaemia, or infection risk
- Infusion reactions, fever, chills, or hypotension
- Hepatic laboratory abnormalities or renal adverse events
- Payload-related toxicity from MMAE such as neuropathy or myelosuppression
ALLERGIC REACTIONS -
Hypersensitivity to azintuxizumab vedotin or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azintuxizumab vedotin should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Strong CYP3A inhibitors or inducers may affect MMAE exposure depending on linker release and metabolism.
- Other neurotoxic or myelosuppressive therapies may increase toxicity.
- Live vaccines should be avoided during significant immune suppression.
- Patients should disclose all chemotherapy, immunotherapy, supplements, and investigational agents.
PREAUTIONS–
- Monitor blood counts, neuropathy, liver and renal function, infusion reactions, and infection signs.
- Dose delay or discontinuation may be needed for severe cytopenia, neuropathy, or organ toxicity.
- Use caution in pregnancy and ensure contraception because MMAE payloads can be embryo-fetal toxic.
WARNINGS –
- ADCs carrying MMAE can cause serious myelosuppression, neuropathy, infection, and infusion reactions.
- Seek urgent care for fever, neurologic symptoms, severe weakness, bleeding, or allergic reaction.
- Keep out of reach of children.
Share on -
. Developed by